Literature DB >> 23959307

CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems.

Zhexue Wu1, Doohyun Lee, Jeongmin Joo, Jung-Hoon Shin, Wonku Kang, Sangtaek Oh, Do Yup Lee, Su-Jun Lee, Sung Su Yea, Hye Suk Lee, Taeho Lee, Kwang-Hyeon Liu.   

Abstract

Albendazole and fenbendazole are broad-spectrum anthelmintics that undergo extensive metabolism to form hydroxyl and sulfoxide metabolites. Although CYP3A and flavin-containing monooxygenase have been implicated in sulfoxide metabolite formation, the enzymes responsible for hydroxyl metabolite formation have not been identified. In this study, we used human liver microsomes and recombinant cytochrome P450s (P450s) to characterize the enzymes involved in the formation of hydroxyalbendazole and hydroxyfenbendazole from albendazole and fenbendazole, respectively. Of the 10 recombinant P450s, CYP2J2 and/or CYP2C19 was the predominant enzyme catalyzing the hydroxylation of albendazole and fenbendazole. Albendazole hydroxylation to hydroxyalbendazole is primarily mediated by CYP2J2 (0.34 μl/min/pmol P450, which is a rate 3.9- and 8.1-fold higher than the rates for CYP2C19 and CYP2E1, respectively), whereas CYP2C19 and CYP2J2 contributed to the formation of hydroxyfenbendazole from fenbendazole (2.68 and 1.94 μl/min/pmol P450 for CYP2C19 and CYP2J2, respectively, which are rates 11.7- and 8.4-fold higher than the rate for CYP2D6). Correlation analysis between the known P450 enzyme activities and the rate of hydroxyalbendazole and hydroxyfenbendazole formation in samples from 14 human liver microsomes showed that albendazole hydroxylation correlates with CYP2J2 activity and fenbendazole hydroxylation correlates with CYP2C19 and CYP2J2 activities. These findings were supported by a P450 isoform-selective inhibition study in human liver microsomes. In conclusion, our data for the first time suggest that albendazole hydroxylation is primarily catalyzed by CYP2J2, whereas fenbendazole hydroxylation is preferentially catalyzed by CYP2C19 and CYP2J2. The present data will be useful in understanding the pharmacokinetics and drug interactions of albendazole and fenbendazole in vivo.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23959307      PMCID: PMC3811268          DOI: 10.1128/AAC.00843-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  42 in total

1.  High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry.

Authors:  Min-Jung Kim; Hyojin Kim; In-June Cha; Jang-Su Park; Ji-Hong Shon; Kwang-Hyeon Liu; Jae-Gook Shin
Journal:  Rapid Commun Mass Spectrom       Date:  2005       Impact factor: 2.419

2.  Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations.

Authors:  H Yamazaki; A Okayama; N Imai; F P Guengerich; M Shimizu
Journal:  Xenobiotica       Date:  2006-12       Impact factor: 1.908

Review 3.  Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes.

Authors:  A D Rodrigues
Journal:  Biochem Pharmacol       Date:  1999-03-01       Impact factor: 5.858

4.  Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A.

Authors:  Kwang-Hyeon Liu; Mi-Gyung Kim; Dong-Jun Lee; Yune-Jung Yoon; Min-Jung Kim; Ji-Hong Shon; Chang Soo Choi; Young Kil Choi; Zeuresenay Desta; Jae-Gook Shin
Journal:  Drug Metab Dispos       Date:  2006-08-08       Impact factor: 3.922

5.  Fenbendazole pharmacokinetics, metabolism, and potentiation in horses.

Authors:  Q A McKellar; C Gokbulut; K Muzandu; H Benchaoui
Journal:  Drug Metab Dispos       Date:  2002-11       Impact factor: 3.922

6.  In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine.

Authors:  Jiang Ping Luo; Sarvesh C Vashishtha; Edward M Hawes; Gordon McKay; Kamal K Midha; Jim Fang
Journal:  Biopharm Drug Dispos       Date:  2011-08-09       Impact factor: 1.627

7.  Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.

Authors:  H Yamazaki; K Inoue; P M Shaw; W J Checovich; F P Guengerich; T Shimada
Journal:  J Pharmacol Exp Ther       Date:  1997-11       Impact factor: 4.030

8.  Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes.

Authors:  H C Rawden; G O Kokwaro; S A Ward; G Edwards
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

9.  Solid-phase synthesis of 1,3,6-trisubstituted-1H-thiazolo[4,5-c][1,2]thiazin-4(3H)one-2,2-dioxide derivatives using traceless linker.

Authors:  Taeho Lee; Ji-Hoon Park; Moon-Kook Jeon; Young-Dae Gong
Journal:  J Comb Chem       Date:  2009-03-09

10.  CYP2E1 substrate inhibition. Mechanistic interpretation through an effector site for monocyclic compounds.

Authors:  Samuel L Collom; Ryan M Laddusaw; Amber M Burch; Petr Kuzmic; Martin D Perry; Grover P Miller
Journal:  J Biol Chem       Date:  2007-12-04       Impact factor: 5.157

View more
  8 in total

1.  Heme Modification Contributes to the Mechanism-Based Inactivation of Human Cytochrome P450 2J2 by Two Terminal Acetylenic Compounds.

Authors:  Hsia-Lien Lin; Haoming Zhang; Vyvyca J Walker; Jaime D'Agostino; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2017-07-11       Impact factor: 3.922

2.  Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets.

Authors:  Mar Siles-Lucas; Adriano Casulli; Roberto Cirilli; David Carmena
Journal:  PLoS Negl Trop Dis       Date:  2018-04-20

Review 3.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

4.  Formation of Both Heme and Apoprotein Adducts Contributes to the Mechanism-Based Inactivation of Human CYP2J2 by 17α-Ethynylestradiol.

Authors:  Hsia-Lien Lin; Haoming Zhang; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2018-03-30       Impact factor: 3.922

5.  Pulmonary Metabolism of Substrates for Key Drug-Metabolizing Enzymes by Human Alveolar Type II Cells, Human and Rat Lung Microsomes, and the Isolated Perfused Rat Lung Model.

Authors:  Katarina Rubin; Pär Ewing; Erica Bäckström; Anna Abrahamsson; Britta Bonn; Satoshi Kamata; Ken Grime
Journal:  Pharmaceutics       Date:  2020-02-01       Impact factor: 6.321

6.  Molecular determinant of substrate binding and specificity of cytochrome P450 2J2.

Authors:  Liang Xu; Liao Y Chen
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

7.  Role of Arginine 117 in Substrate Recognition by Human Cytochrome P450 2J2.

Authors:  Pierre Lafite; François André; Joan P Graves; Darryl C Zeldin; Patrick M Dansette; Daniel Mansuy
Journal:  Int J Mol Sci       Date:  2018-07-16       Impact factor: 5.923

8.  High-Fat Breakfast Increases Bioavailability of Albendazole Compared to Low-Fat Breakfast: Single-Dose Study in Healthy Subjects.

Authors:  Dolores Ochoa; Miriam Saiz-Rodríguez; Esperanza González-Rojano; Manuel Román; Sergio Sánchez-Rojas; Aneta Wojnicz; Ana Ruiz-Nuño; Alfredo García-Arieta; Francisco Abad-Santos
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.